Change currency
Alzheimer’s Disease Patients & Market Worldwide (RNR00023)
Future Scenario (2010 – 2015) & Drugs AnalysisAlzheimer’s is a complex disease and there is no single “magic bullet” available in the market to prevent or cure it. Though many marketed drugs have been approved for Alzheimer’s...		Jun 2011 £600
Alzheimer's and Parkinson's Disease (GIA00077)
This report analyzes the worldwide markets for Alzheimer's and Parkinson's Disease in Millions of US$. The Major product segments Analyzed are Anti-Alzheimer's Disease Drugs (Cholinesterase Inhibitors, & NMDARA), and Anti-Parkinson's...		May 2008 £2,490
Alzheimer's Disease (GDA00773)
Pipeline Assessment and Market Forecasts to 2017GlobalData, the industry analysis specialist, has released its new report, ""Alzheimer's Disease - Pipeline Assessment and Market Forecasts to 2017"". The report is an essential source of information and...		Nov 2010 £1,260
Alzheimer's Disease: Lifecycle Pharma Forecast, 2012-2035 – Europe (SLT00002)
SlideScript's Lifecycle Pharma Forecast reports deliver essential therapy area benchmarking data and quantitative market estimates projected across multiple regions and individual countries. Data-rich tables enable rapid understanding of market values,...		Feb 2012 £3,400
Alzheimer's Disease Partnering 2007-2012 (CTP00213)
The Alzheimer's Disease Partnering 2007-2012 provides understanding and access to the alzheimer's disease partnering deals and agreements entered into by the worlds leading healthcare companies . The report provides an...		May 2012 £630
Alzheimer's Disease: Competing Treatments and Market Entry Considerations (BPR00018)
Presents the findings of a clinical survey of current treatment practices for Alzheimer’s Disease (AD). This was carried out following the participation of more than 220 physicians, practicing predominantly in...		Jun 2010 £1,500
Alzheimer's disease -Technologies, Markets and Companies (JAI00023)
Alzheimer's disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable...		May 2012 £2,210
Increasing Disease Burden of Alzheimer's Disease (GDA14027)
Is There a Solution in Sight?Summary GlobalData's report, "Increasing Disease Burden of Alzheimer's Disease - Is There a Solution in Sight? " provides key information on current available treatment of Alzheimer's disease, drivers and barriers for...		Mar 2011 £315
Alzheimer's Disease: Lifecycle Pharma Forecast, 2012-2035 - BRIC: Brazil, Russia, India, China (SLT00004)
SlideScript's Lifecycle Pharma Forecast reports deliver essential therapy area benchmarking data and quantitative market estimates projected across multiple regions and individual countries. Data-rich tables enable rapid understanding of market values,...		Feb 2012 £3,400
Alzheimer's Disease: Lifecycle Pharma Forecast, 2012-2035 - North America and Asia-Pacific (SLT00003)
SlideScript's Lifecycle Pharma Forecast reports deliver essential therapy area benchmarking data and quantitative market estimates projected across multiple regions and individual countries. Data-rich tables enable rapid understanding of market values,...		Feb 2012 £3,400
Understanding Alzheimer's Disease (PRC00021)
Risk Factors, Genetics and Clinical ResearchAlzheimer's disease (AD), also called Alzheimer disease, Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer's, is the most common form of dementia. This incurable, degenerative, and terminal disease...		Nov 2010 £93
The 10th International Conference on Alzheimer's and Parkinson's Diseases (GDA14040)
Post-Conference Review and AnalysisSummary GlobalData, the industry analysis specialist, has released its new conference alert, "The 10th International Conference on Alzheimer's and Parkinson's Diseases". The conference alert is an essential source of information and...		Mar 2011 £630
Early Diagnosis of Alzheimer's Disease (GDA14030)
Benefits, Challenges and Recent DevelopmentsSummary GlobalData's report, "Early Diagnosis of Alzheimer's Disease - Benefits, Challenges and Recent Developments" provides key update on the landmark on the early diagnosis of Alzheimer's Disease. It highlights the benefits,...		Mar 2011 £315
Alzheimer’s Disease Immunotherapy Pipeline (BPR00015)
Vaccines, Therapeutic Antibodies and Emerging StrategiesCurrent drug treatments for Alzheimer’s Disease (AD) are dominated by two drug classes: the cholinesterase inhibitors (e.g. Aricept®) and, more recently, an NMDA receptor antagonist (e.g. Ebixa®). While these drugs...		Jul 2010 £1,500
Alzheimer's Disease Therapeutics and Diagnostics (BCC00340)
Global MarketsIntroduction Study Goals and Objectives BCC's Goal in Conducting This Study Was to Determine The Current Status of The Alzheimer's Disease Treatments and Diagnostics and Assess The Growth Potential of This...		Jan 2010 £3,060
U.S. Alzheimer's Disease Medication Market (FRS02026)
This research service provides an indepth analysis of factors affecting the growth of the U.S. Alzheimer's disease medication market over the period 2006-2016. Following an introduction to the market, which...		Aug 2010 £3,785
Alzheimer's Disease (BPR00012)
Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011This report presents a comprehensive review of autoantibodies, and pipeline vaccines and therapeutic antibodies, in Alzheimer’s disease (AD). Currently, drug treatments for AD are dominated by cholinesterase inhibitors and an...		Mar 2011 £1,500
Image-Based Biomarkers in Alzheimer's Disease (BPR00009)
2011his report provides an overview of image-based biomarkers associated with Alzheimer’s disease (AD), that have potential in differential diagnosis, in following treatment, in clinical trials and drug discovery. AD biomarkers...		Feb 2011 £350
Alzheimer's Disease Biomarkers in Cerebrospinal Fluid and Blood (BPR00005)
2011This report provides an overview of biomarkers associated with Alzheimer’s disease (AD) found in cerebrospinal fluid and blood, that have potential in differential diagnosis, in following treatment, in clinical trials...		Feb 2011 £650
Alzheimer's Disease Market analysis and forecasts, 2007-2012, 2017 & 2022 (VIS00053)
Please Note: Reports are sold based on the user licenses indicated. The reports will be accessible in Flash format via an online reading room on the publisher website, allowing viewing...		Oct 2007 £1,499
Novel Targeted Therapies Hold Promise of Reversing the Progress of Alzheimer's Disease (AD) (GDA07703)
Novel Targeted Therapies Hold Promise of Reversing the Progress of Alzheimer's Disease (AD) Summary GlobalData's report, "Novel Targeted Therapies Hold Promise of Reversing the Progress of Alzheimer's Disease (AD)" provides key data,...		Jan 2011 £315
CNS Drug Discoveries: Alzheimer's Disease Chapter (ESP00552)
Alzheimer's disease By 2014, there will be considerable change in the Alzheimer's disease (AD) market due to generic competition, better utilisation of acetylcholinesterase inhibitors and new product launches which, for the...		Apr 2012 £595
Stakeholder Insight: Alzheimer's Disease (DAT04407)
Prescribing trends indicate that neurologists are not adhering to guidelinesIntroduction A lack of prescriber adherence to both marketing licenses and pharmacoeconomic guidelines represents both a challenge and opportunity for pharmaceutical companies marketing current Alzheimer's disease drugs. Indication expansion between disease...		Dec 2006 £8,350
Tau and Amyloid Beta Targeted Therapy of Alzheimer's Disease (LME00122)
Competitor AnalysisThe present Competitive Intelligence Report about Tau and Amyloid Beta Targeted Therapy of Alzheimer's Disease provides a competitor evaluation in the field of therapeutic vaccines, antibodies and small molecules targeting...		Aug 2010 £580
Medivation, Inc. (MDVN) - Pharmaceuticals & Healthcare (GDA13463)
Deals and Alliances ProfileSummary Medivation, Inc. (Medivation) is a biopharmaceutical company engaged in the research and development of small molecule drugs. The company initiates drug development programs for the development of candidates that address...		Mar 2012 £160